检索历史清除

首页> Future virology> Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).

导出 LinkOut

翻译打印收藏纠错

作者： Arantxa,Horga ; Rebecca,Saenz ; Gürdal,Yilmaz ; Abraham,Simón-Campos ; Keith,Pietropaolo ; William J,Stubbings ; Neil,Collinson ; Laura,Ishak ; Barbara,Zrinscak ; Bruce,Belanger ; Catherine,Granier ; Kai,Lin ; Aeron,C Hurt ; Xiao-Jian,Zhou ; Steffen,Wildum ; Janet,Hammond

关键词 AT-527 COVID-19 SARS-CoV-2 bemnifosbuvir oral outpatient

DOI 10.2217/fvl-2023-0115

PMID 37928891

发布时间 2024-10-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交